沙利度胺

  • 网络Thalidomide
沙利度胺沙利度胺
  1. 阳性对照组、沙利度胺A组、B组抑瘤率分别为83.8%、50.1%、41.5%。

    The cancer suppressive rate of thalidomide A and B groups were 50.1 % and 41.5 % respectively .

  2. N糖基取代的沙利度胺新衍生物对人鼻咽癌细胞耐药逆转作用研究

    Reversal Effect of A Novel N-sugar Substituted Thalidomide Analogue on Multidrug Resistant Human Nasopharyngeal Carcinoma Cells

  3. 近年来沙利度胺被应用于MM的治疗中,并取得了巨大成功。

    Recent years thalidomide ( Thd ) has been applied for MM and succeeds in treating MM .

  4. 沙利度胺对类风湿关节炎患者VEGF表达的影响

    Study on the Effects of Thalidomide on VEGF Expression in Patients with Rheumatoid Arthritis

  5. 沙利度胺联合PC方案对非小细胞肺癌患者疗效/血清VEGF的影响

    Effect of thalidomide combined with PC regimen on efficacy / serum VEGF in patients with non-small cell lung cancer

  6. 方法:用Sigma公司生产的沙利度胺原料药。

    Methods : Thalidomide used as crude drug was bought from Sigma company .

  7. 国内沙利度胺治疗多发性骨髓瘤疗效与安全性的Meta分析

    Effectiveness and Safety of Thalidomide for Treating Multiple Myeloma in China : A Meta-analysis

  8. 沙利度胺对CIA鼠关节滑膜中MCP-1的影响

    Effect of thalidomide on MCP-1 in synovial joints of rats

  9. 中大剂量沙利度胺联合TACE治疗原发性肝癌临床研究

    Clinical research on middle-high dose Thalidomide Combined TACE treatment of primary liver cancer

  10. 一些有前景的药物如沙利度胺、蛋白酶体抑制剂、砷剂等的应用使MM的治疗得到了极大的突破。

    Applications of several perspective drugs such as Thalidomide , proteasomes inhibitor , arsenical and other agents bring galactic breakthrough to the treatments of MM .

  11. 现代的诱导治疗方案、造血干细胞移植、沙利度胺及新型蛋白酶体抑制剂的应用,MM的疗效得到不断提高。

    With the development of modern induction therapy , hematopoietic stem cell transplantation and the application of thalidomide , the efficacy of MM are rising .

  12. 沙利度胺联合VAD方案化疗对多发性骨髓瘤病人细胞因子影响

    The effects of Thalidomide-Combination chemotherapy on cytokine in patients with multiple myeloma

  13. 沙利度胺联合改良VAD方案治疗多发性骨髓瘤临床观察

    Clinical investigation of thalidomide with VAD in the treatment of multiple myeloma

  14. 沙利度胺与孕三烯酮联合应用对EMs模型大鼠异位移植物的抑制具有协同作用。

    Thalidomide in combination with gestrinone had synergistic action on the depressant effect on the ectopic implants in EMs rats .

  15. 利用该动物模型观察沙利度胺对癌症恶病质的治疗作用,以细胞因子(TNF-α和IL-6)为靶点,研究沙利度胺治疗恶病质的作用机制。

    To observe the effect of thalidomide on cancer cachexia and research the mechanism in cytokine level ( TNF - α and IL-6 ) .

  16. 探讨沙利度胺联合小剂量MP方案化疗治疗老年多发性骨髓瘤的临床疗效及不良反应。

    To explore the effectivity and adverse reaction of thalidomide combined small-dose MP plan in treatment of senile multiple myeloma ( MM ) .

  17. 方法:12例多发性骨髓瘤均采用改良VAD方案联合沙利度胺治疗。

    Methods : 12 patients with multiple myeloma were administrated with modified VAD regimen combined with thalidomide .

  18. 沙利度胺对于M7细胞没有明显抗增殖效应及诱导其凋亡的作用。

    Thalidomide has no notable anti-proliferative and apoptosis-induced effects on M7 cell .

  19. 目的:观察沙利度胺(thalidomide)对不同类型红斑狼疮(LE)皮肤损害的临床疗效。

    Objective : To observe the curative effects of thalidomide on different types of cutaneous lesions of lupus erythematosus ( LE ) .

  20. 沙利度胺联合CHOP方案不良反应发生率大多轻微,大部分患者可以耐受,生活质量较高。

    Most of the adverse reactions of the thalidomide combined with CHOP chemotherapy were mild , most patients could tolerate and had higher quality of life .

  21. 目的:观察改良VAD方案联合沙利度胺治疗多发性骨髓瘤的临床疗效和不良反应。

    Objective : To observe the efficacy and side effects of modified VAD regimen combined with thalidomide in treatment of multiple myeloma .

  22. 目的探讨沙利度胺联合VAD方案治疗多发性骨髓瘤(multiplemyeloma,MM)的临床疗效及治疗前后血管内皮生长因子(VascularEndothelialGrowthFactor,VEGF)水平变化。

    Objective To study the curative effect and side effect of thalidomide incorporation with VAD in the treatment of multiple myeloma and the significance of the change of serum VEGF ( vascular endothelial growth factor ) concentration in multiple myeloma .

  23. 目的:观察沙利度胺联合三氧化二砷和维甲酸治疗低危骨髓增生异常综合征(MDS)的疗效和不良反应。

    Objective : To observe the therapeutic effects and side-effects of thalidomide combined with arsenious oxide and retinoic acid for the treatment of low-risk myelodysplastic syndromes ( MDS ) .

  24. 沙利度胺(酞胺哌啶酮thalidomide)属于非巴比妥类药物,最早作为镇静止吐药物用于临床,后发现具有严重的致畸作用而被禁用。

    Thalidomide , a non-barbiturate drug , is used as a sedative antiemetic drug , and shows a significant teratogenic effect , has once been banned .

  25. 目的评价T-VAD(沙利度胺联合VAD方案)和VAD方案治疗多发性骨髓瘤的疗效。

    Objective To compare the curative effect of T-VAD regimen and VAD regimen in the treatment of multiple myeloma .

  26. 人MDS荷瘤小鼠模型的建立及砷剂、沙利度胺在荷瘤小鼠体内抗瘤作用与机制的研究

    The Establishment of a Human MDS Mice Model and the Study of Anti-tumor Effect and Mechanisms of Arsenic Trioxide Alone or in Combination with Thalidomide for Therapy on Hum - MDS Mice Model

  27. 经皮椎板间隙入路L5S1椎间盘切除术沙利度胺对大鼠神经根疼痛影响的实验研究

    Percutaneous endoscopic laser-assisted discectomy on L_5S_1 herniated nucleus pulposus through trans-interlaminar approach The experimental investigation of thalidomide influence on radicular pain caused by autologous nucleus pulposus in rats

  28. 第二天起沙利度胺组给予沙利度胺(100mg·kg-1)饲料喂养,其余两组在相同条件下给予普通饲料喂养。

    From the second day the thalidomide group were fed with thalidomide ( 100mg · kg-1 ) which was mixed into normal diet , while the other two groups with normal diet instead .

  29. 沙利度胺(thalidomide,Thal)是作用于骨髓微环境的药物之一,我们通过观察沙利度胺对难治、复发多发性骨髓瘤(multiplemyeloma,MM)患者骨髓微环境的影响,进一步了解Thal的作用机制。

    Thalidomide is one of agents targeting the bone marrow microenvironment . This study was conducted to investigate the mechanism of thalidomide by observation of influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma .

  30. 方法随机分为模型对照组、100mg·kg-·1d-1沙利度胺治疗组、200mg·kg-·1d-1沙利度胺治疗组和正常对照组。

    Methods Rats were randomly divided into a control group , 100 mg · kg-1 · d-1 thalidomide-treated group , 200 mg · kg-1 · d-1 thalidomide-treated group and a normal control group .